Experts are rapidly investigating retatrutide, a promising drug created by Eli Lilly, as a potential breakthrough in physique management. Distinct from many previous approaches, retatrutide is a twin-action agonist targeting equally GLP-1 and GIP, hormones that impact satiety and blood glucose c